Galectin Therapeutics, Inc. (GALT)
3.71
+0.07
(+1.92%)
USD |
NASDAQ |
Oct 15, 16:00
3.73
+0.02
(+0.54%)
After-Hours: 20:00
Galectin Therapeutics Research and Development Expense (Quarterly) : 2.135M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 2.135M |
| March 31, 2026 | 2.231M |
| December 31, 2025 | 1.933M |
| September 30, 2025 | 2.611M |
| June 30, 2025 | 3.261M |
| March 31, 2025 | 6.485M |
| December 31, 2024 | 11.11M |
| September 30, 2024 | 7.595M |
| June 30, 2024 | 9.813M |
| March 31, 2024 | 8.054M |
| December 31, 2023 | 8.228M |
| September 30, 2023 | 7.732M |
| June 30, 2023 | 7.371M |
| March 31, 2023 | 8.799M |
| December 31, 2022 | 9.007M |
| September 30, 2022 | 6.598M |
| June 30, 2022 | 8.074M |
| March 31, 2022 | 8.058M |
| December 31, 2021 | 5.856M |
| September 30, 2021 | 6.613M |
| June 30, 2021 | 6.45M |
| March 31, 2021 | 4.899M |
| December 31, 2020 | 6.371M |
| September 30, 2020 | 4.78M |
| June 30, 2020 | 4.681M |
| Date | Value |
|---|---|
| March 31, 2020 | 2.144M |
| December 31, 2019 | 3.796M |
| September 30, 2019 | 1.503M |
| June 30, 2019 | 1.522M |
| March 31, 2019 | 0.646M |
| December 31, 2018 | 1.192M |
| September 30, 2018 | 1.505M |
| June 30, 2018 | 1.476M |
| March 31, 2018 | 2.298M |
| December 31, 2017 | 1.002M |
| September 30, 2017 | 3.503M |
| June 30, 2017 | 3.444M |
| March 31, 2017 | 3.772M |
| December 31, 2016 | 3.433M |
| September 30, 2016 | 3.289M |
| June 30, 2016 | 4.226M |
| March 31, 2016 | 4.377M |
| December 31, 2015 | 2.914M |
| September 30, 2015 | 4.464M |
| June 30, 2015 | 2.60M |
| March 31, 2015 | 3.136M |
| December 31, 2014 | 2.08M |
| September 30, 2014 | 1.979M |
| June 30, 2014 | 1.594M |
| March 31, 2014 | 2.772M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Mirum Pharmaceuticals, Inc. | 90.29M |
| ACADIA Pharmaceuticals, Inc. | 81.56M |
| Alnylam Pharmaceuticals, Inc. | 413.13M |
| Anika Therapeutics, Inc. | 7.341M |
| Savara, Inc. | 21.95M |